[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Yin H, Cheng SH, Zhang J, Ma L, Gao Y, Li D, Lim CC: Corticospinal tract degeneration in amyotrophic lateral sclerosis: a diffusion tensor imaging and fibre tractography study. Ann Acad Med Singapore; 2008 May;37(5):411-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLINICAL PICTURE: We studied 8 ALS patients and 12 normal volunteers using diffusion tensor imaging (DTI) and fibre tractography using fibre assignment by continuous tracking (FACT) to study the fibres of the CST and the posterior thalamic radiation (PTR), a nonmotor tract.
  • The fibre bundles of the CST, but not the PTR, were significantly reduced (P <0.05) in patients compared to normal volunteers.
  • CONCLUSION: Fibre tractography can visualise axonal degeneration in the CST and may provide supplementary information about upper motor neuron disease in ALS patients.


2. Liu Y, Balériaux D, Kavec M, Metens T, Absil J, Denolin V, Pardou A, Avni F, Van Bogaert P, Aeby A: Structural asymmetries in motor and language networks in a population of healthy preterm neonates at term equivalent age: a diffusion tensor imaging and probabilistic tractography study. Neuroimage; 2010 Jun;51(2):783-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No asymmetry was found in the sensory part of the STR, the anterior thalamic radiations (ATR), and posterior thalamic radiations (PTR) neither in the fronto-parietal part of the SLF.

  • MedlinePlus Health Information. consumer health - Premature Babies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20206706.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Oswiecimska JM, Ziora KT, Ziora KN, Pindycka-Piaszczynska M, Zajecki W, Pikiewicz-Koch A, Stojewska M: Growth hormone therapy in boy with panhypopituitarism may induce pilomatricoma recurrence: case report. Neuro Endocrinol Lett; 2008 Feb;29(1):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone therapy in boy with panhypopituitarism may induce pilomatricoma recurrence: case report.
  • Pilomatricoma is usually a solitary subcutaneous nodule.
  • Pilomatricoma occurrence in patients with growth hormone (GH) deficiency has not been reported, yet.
  • We report a 14-year-old boy with pilomatricoma and panhypopituitarism.
  • After GH therapy had been started, we observed two relapses of previously completely excised pilomatricoma in the same location and a new pilomatricoma formation on the chin.
  • [MeSH-major] Growth Hormone / adverse effects. Growth Hormone / therapeutic use. Hair Diseases / chemically induced. Hypopituitarism / drug therapy. Neoplasm Recurrence, Local / chemically induced. Pilomatrixoma / chemically induced. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Dose-Response Relationship, Drug. Humans. Insulin-Like Growth Factor I / metabolism. Male

  • Genetic Alliance. consumer health - Pituitary hormone deficiency, combined 2.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283258.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


Advertisement
4. Tawfiq N, Lakhrib N, Mharech A, Benchakroun N, Benider A, Benkirane A, Zamiati S, Mansouri I, Roubal M, Kadiri Fatmi ME, Elbenna N, Abdelouafi A: [Malignant pilomatrixoma of head and neck. A case report]. Cancer Radiother; 2010 Jun;14(3):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pilomatrixoma of head and neck. A case report].
  • [Transliterated title] Le pilomatricome malin cervical métastatique : à propos d'un cas.
  • We report the case of a 66-year-old patient with a pilomatrix carcinoma from the right submandibular region with pulmonary and cerebral metastases.
  • We tried at first a doxorubicine and cisplatine chemotherapy because of the considerable locoregional extension and the existence of pulmonary metastases.
  • The patient response to three cures of chemotherapy was spectacular with a partial clinical response (75%) and a partially cleaned-up chest observed in the radiological evaluation.
  • In the 5th cycle of chemotherapy following the same protocol, the patient presented a relapse with cerebral metastases.
  • The patient received hypofractionated radiotherapy on the brain followed by etoposide and cisplatine chemotherapy, then oral vinorelbine.
  • The patient died of progressive disease after 32 weeks.
  • [MeSH-major] Facial Neoplasms / pathology. Pilomatrixoma / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Pilomatrixoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20434933.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


5. Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G: A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Br J Cancer; 2001 Nov 30;85(11):1722-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A PTH-rP-derived peptide, designated PTR-4 was identified, which is capable to bind HLA-A2.1 molecules and to generate PTH-rP-specific cytotoxic T cell (CTL) lines from healthy HLA-A2.1(+) individual peripheral-blood-mononuclear-cells (PBMC).
  • In this model, we investigated the in vitro possibility of generating an efficient PTH-rP specific CTL response by cyclical stimulations with IL-2 and PTR-4 peptide-pulsed autologous dendritic cells (DC), of HLA-A2.1(+) tumour infiltrating lymphocytes (TIL) derived from a patient with metastatic prostate carcinoma.
  • A T cell line generated in this way (called TM-PTR-4) had a CD3(+), CD5(+), CD4(-), CD8(+), CD45(Ro+), CD56(-) immunophenotype and a HLA-A2.1 restricted cytotoxic activity to PTR-4-peptide pulsed CIR-A2 (HLA-A2.1(+)) target cells, PTH-rP(+)/HLA-A2.1(+) CIR-A2 transfected with PTH-rP gene, prostate carcinoma LNCaP cells, and autologous metastatic prostate cancer cells (M-CaP).
  • Our results provide evidence that PTR-4 peptide-pulsed autologous DC may break the tolerance of human TIL against the autologous tumour by inducing a PTH-rP-specific CTL immune reaction.
  • In conclusion PTR-4 peptide-pulsed autologous DC may be a promising approach for vaccine-therapy and antigen-specific CTL adoptive immunotherapy of hormone-resistant prostrate cancer.
  • [MeSH-major] Dendritic Cells / immunology. Interleukin-2 / pharmacology. Lymphocytes, Tumor-Infiltrating / immunology. Prostatic Neoplasms / therapy. Proteins / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Bone Neoplasms / immunology. Bone Neoplasms / secondary. Cytotoxicity Tests, Immunologic. Cytotoxicity, Immunologic / drug effects. Cytotoxicity, Immunologic / immunology. Epitopes / immunology. Flow Cytometry. HLA-A2 Antigen / immunology. Humans. Immunophenotyping. Male. Neoplasm Metastasis. Oligopeptides / immunology. Parathyroid Hormone-Related Protein. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2001 Cancer Research Campaign
  • [Cites] Eur J Cancer. 2001 May;37(7):892-902 [11313178.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1690-5 [10415076.001]
  • [Cites] Semin Hematol. 1985 Jan;22(1):27-40 [3155876.001]
  • [Cites] J Immunol Methods. 1987 Aug 24;102(1):127-41 [3305708.001]
  • [Cites] J Immunol. 1989 May 15;142(10):3714-25 [2785562.001]
  • [Cites] J Clin Invest. 1990 Mar;85(3):955-61 [2179270.001]
  • [Cites] Nature. 1990 May 31;345(6274):449-52 [2342577.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6248-55 [2119252.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):273-6 [1670640.001]
  • [Cites] Semin Oncol. 1991 Aug;18(4 Suppl 5):11-5 [1925624.001]
  • [Cites] Eur J Cancer. 1991;27(11):1393-5 [1835854.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Cancer Immunol Immunother. 1992;34(4):272-8 [1371427.001]
  • [Cites] Biotherapy. 1992;5(1):47-61 [1389902.001]
  • [Cites] Cancer. 1993 Feb 1;71(3 Suppl):880-6 [8428342.001]
  • [Cites] Cancer Immunol Immunother. 1993 May;36(5):315-22 [8477417.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1430-6 [8512828.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 18;85(16):1294-302 [8340941.001]
  • [Cites] Eur J Immunol. 1993 Sep;23(9):2072-7 [8370389.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] Cancer Immunol Immunother. 1994 Jul;39(1):15-21 [8044822.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1):74-80 [7855622.001]
  • [Cites] Immunol Today. 1995 Mar;16(3):117-21 [7718082.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):285-90 [7540894.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):982-90 [7629885.001]
  • [Cites] Eur J Immunol. 1995 Sep;25(9):2588-97 [7589131.001]
  • [Cites] J Immunol Methods. 1996 Sep 27;196(2):137-51 [8841452.001]
  • [Cites] Cancer Treat Rev. 1996 Jul;22(4):289-331 [9025785.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 19;89(4):293-300 [9048833.001]
  • [Cites] Life Sci. 1997;60(23):2035-41 [9180357.001]
  • [Cites] Cell Immunol. 1997 Aug 25;180(1):70-83 [9316641.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1572-80 [9362424.001]
  • [Cites] Cancer Immunol Immunother. 1998 May;46(3):121-7 [9625535.001]
  • [Cites] Prostate. 1998 Jun 15;36(1):39-44 [9650914.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(2):210-3 [9741323.001]
  • [Cites] Ann Oncol. 1999 Jan;10(1):21-7 [10076717.001]
  • [Cites] Adv Immunol. 1999;72:255-324 [10361578.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1968;97:51-76 [4179067.001]
  • (PMID = 11742494.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epitopes; 0 / HLA-A2 Antigen; 0 / Interleukin-2; 0 / Oligopeptides; 0 / PTHLH protein, human; 0 / Parathyroid Hormone-Related Protein; 0 / Proteins
  • [Other-IDs] NLM/ PMC2363980
  •  go-up   go-down


6. Mori S, Kaufmann WE, Davatzikos C, Stieltjes B, Amodei L, Fredericksen K, Pearlson GD, Melhem ER, Solaiyappan M, Raymond GV, Moser HW, van Zijl PC: Imaging cortical association tracts in the human brain using diffusion-tensor-based axonal tracking. Magn Reson Med; 2002 Feb;47(2):215-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffusion-tensor fiber tracking was used to identify the cores of several long-association fibers, including the anterior (ATR) and posterior (PTR) thalamic radiations, and the uncinate (UNC), superior longitudinal (SLF), inferior longitudinal (ILF), and inferior fronto-occipital (IFO) fasciculi.
  • Guidelines were developed to reproducibly track these fibers in vivo.
  • As a first illustration of this technical capability, a reduction in brain connectivity in a patient with a childhood neurodegenerative disease (X-linked adrenoleukodystrophy) was demonstrated.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11810663.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH52886; United States / NIA NIH HHS / AG / AG016028; United States / NICHD NIH HHS / HD / HD24061; United States / NCRR NIH HHS / RR / RR15241; United States / NIBIB NIH HHS / EB / P41 EB015909; United States / NICHD NIH HHS / HD / HD37931
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


7. Fan GG, Yu B, Quan SM, Sun BH, Guo QY: Potential of diffusion tensor MRI in the assessment of periventricular leukomalacia. Clin Radiol; 2006 Apr;61(4):358-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quantitative analysis was performed using the regions of interest (ROI) method settled on the central part of all identifiable WM fibres, including the corticospinal tract (CST) in the brainstem, middle cerebellar peduncle (MCP), medial lemniscus (ML), anterior/posterior limb of internal capsule (ICAL/ICPL), arcuate fasciculus (AF), posterior thalamic radiation (PTR), genu of corpus callosum (GCC), splenium of corpus callosum (SCC), corona radiata (CR), cingulum (CG), and superior longitudinal fasciculus (SLF).
  • All data were analysed by paired Student's t-test.
  • A p-value of less than 0.05 was considered to indicate statistical significance.
  • However, the ICPL, AF, PTR, CR, CG, SLF and corpus callosum, were all attenuated in size.
  • All 12 cases of PVL showed a significant mean FA reduction in the ICPL, AF, PTR, CR, CG, SLF, SCC, and GCC in comparison with the ipsilateral regions of healthy controls (p<0.05).
  • However, there were no statistically significant differences of the ICAL, ML, MCP, and brainstem CST when analysed using a two-tailed Student's t-test for paired data (p>0.01).


8. Kaplan E, Naeser MA, Martin PI, Ho M, Wang Y, Baker E, Pascual-Leone A: Horizontal portion of arcuate fasciculus fibers track to pars opercularis, not pars triangularis, in right and left hemispheres: a DTI study. Neuroimage; 2010 Aug 15;52(2):436-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We utilized diffusion tensor imaging (DTI) in eight healthy subjects (5 M) to track pathways in the horizontal mid-portion of the AF (hAF) to subregions of Broca's area - pars triangularis (PTr) and pars opercularis (POp); and to ventral premotor cortex (vPMC) in the right and left hemispheres (RH, LH).
  • Only 1/8 subjects showed fiber tracts between PTr and hAF in the RH (also, only 1/8 in the LH).
  • In contrast to PTr, 5/8 subjects showed fiber tracts between POp and hAF in the RH (8/8 in the LH).
  • Thus, although the present DTI study showed almost no pathways between PTr and hAF in the RH (and in the LH), robust pathways were observed between POp and/or vPMC with hAF in the RH (and in LH).

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Hum Brain Mapp. 2006 Oct;27(10):828-35 [16541458.001]
  • [Cites] Neuroimage. 2007 Jan 1;34(1):144-55 [17070705.001]
  • [Cites] J Anat. 2007 Oct;211(4):534-55 [17727624.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17163-8 [17939998.001]
  • [Cites] Brain Res Cogn Brain Res. 2000 Jan;9(1):19-33 [10666553.001]
  • [Cites] J Anat. 2000 Oct;197 Pt 3:335-59 [11117622.001]
  • [Cites] J Cogn Neurosci. 2001 May 15;13(4):419-29 [11388916.001]
  • [Cites] Magn Reson Med. 2002 Feb;47(2):215-23 [11810663.001]
  • [Cites] Annu Rev Neurosci. 2002;25:151-88 [12052907.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):803-12 [12194878.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):435-55 [12489094.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):468-80 [12489096.001]
  • [Cites] J Cogn Neurosci. 2003 Jan 1;15(1):71-84 [12590844.001]
  • [Cites] Brain Lang. 2003 Jun;85(3):385-95 [12744950.001]
  • [Cites] Ann Neurol. 2003 Sep;54(3):310-20 [12953263.001]
  • [Cites] Cognition. 2004 May-Jun;92(1-2):67-99 [15037127.001]
  • [Cites] Cognition. 2004 May-Jun;92(1-2):179-229 [15037130.001]
  • [Cites] J Cogn Neurosci. 2004 Mar;16(2):289-300 [15068598.001]
  • [Cites] Neuroimage. 2004 May;22(1):42-56 [15109996.001]
  • [Cites] Annu Rev Neurosci. 2004;27:169-92 [15217330.001]
  • [Cites] Nat Neurosci. 2004 Jul;7(7):701-2 [15184903.001]
  • [Cites] Cereb Cortex. 2004 Sep;14(9):945-51 [15115737.001]
  • [Cites] Brain. 1965 Jun;88(2):237-94 [5318481.001]
  • [Cites] Neuropsychologia. 1977;15(3):371-83 [854156.001]
  • [Cites] Neurology. 1978 Apr;28(4):311-24 [565019.001]
  • [Cites] Arch Neurol. 1981 Sep;38(9):561-9 [7271534.001]
  • [Cites] Can J Psychol. 1983 Mar;37(1):107-31 [6640436.001]
  • [Cites] J Comp Neurol. 1984 Sep 1;228(1):105-16 [6480903.001]
  • [Cites] Brain. 1989 Feb;112 ( Pt 1):1-38 [2917272.001]
  • [Cites] Neurology. 1990 Feb;40(2):353-62 [2300260.001]
  • [Cites] Radiology. 1990 Aug;176(2):439-45 [2367658.001]
  • [Cites] Acta Neurol Scand. 1991 Aug;84(2):114-26 [1719738.001]
  • [Cites] J Neurophysiol. 1995 Nov;74(5):2163-73 [8592204.001]
  • [Cites] Brain. 1996 Jun;119 ( Pt 3):919-31 [8673502.001]
  • [Cites] Neuroreport. 1995 Nov 27;6(17):2309-13 [8747143.001]
  • [Cites] Brain Lang. 1998 Mar;62(1):89-106 [9570881.001]
  • [Cites] Hum Brain Mapp. 1997;5(2):79-83 [10096412.001]
  • [Cites] Neuroimage. 1999 Jul;10(1):15-35 [10385578.001]
  • [Cites] J Comp Neurol. 1999 Sep 20;412(2):319-41 [10441759.001]
  • [Cites] Ann Neurol. 2005 Jan;57(1):8-16 [15597383.001]
  • [Cites] Neuroimage. 2005 Feb 1;24(3):656-66 [15652301.001]
  • [Cites] Physiology (Bethesda). 2005 Feb;20:60-9 [15653841.001]
  • [Cites] Brain Lang. 2005 Apr;93(1):95-105 [15766771.001]
  • [Cites] Cereb Cortex. 2005 Jun;15(6):854-69 [15590909.001]
  • [Cites] Neuroimage. 2008 Jan 1;39(1):1-9 [17928238.001]
  • [Cites] J Physiol Paris. 2008 Jan-May;102(1-3):31-4 [18440208.001]
  • [Cites] Cortex. 2008 Sep;44(8):953-61 [18614162.001]
  • [Cites] Cereb Cortex. 2008 Nov;18(11):2471-82 [18281301.001]
  • [Cites] Brain Lang. 2008 Oct;107(1):16-43 [17977592.001]
  • [Cites] Neuroimage. 2007 Apr 15;35(3):1064-76 [17320414.001]
  • [Cites] Nat Rev Neurosci. 2007 May;8(5):393-402 [17431404.001]
  • [Cites] J Neurosci. 2008 Nov 5;28(45):11435-44 [18987180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):18035-40 [19004769.001]
  • [Cites] Brain Lang. 2009 Apr;109(1):29-48 [19155059.001]
  • [Cites] Brain Lang. 2009 Oct;111(1):20-35 [19695692.001]
  • [Cites] Brain Lang. 2010 Jan;112(1):54-76 [18996582.001]
  • [Cites] Brain Lang. 2010 Apr;113(1):45-50 [20159655.001]
  • [Cites] Cogn Behav Neurol. 2010 Mar;23(1):29-38 [20299861.001]
  • [Cites] Neuroreport. 2005 May 31;16(8):791-4 [15891571.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1235-8 [15988526.001]
  • [Cites] Neurocase. 2005 Jun;11(3):182-93 [16006338.001]
  • [Cites] J Neurosci. 2005 Aug 31;25(35):8010-6 [16135758.001]
  • [Cites] J Neurosci. 2005 Sep 28;25(39):8854-66 [16192375.001]
  • [Cites] Neuroimage. 2006 Jul 1;31(3):968-80 [16530430.001]
  • [Cites] Neuroimage. 2006 Aug 1;32(1):388-99 [16632380.001]
  • [Cites] Cereb Cortex. 2006 Oct;16(10):1418-30 [16306320.001]
  • (PMID = 20438853.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / P30 DC05207; United States / PHS HHS / / K24RRO18875; United States / NIDCD NIH HHS / DC / P30 DC005207; United States / NCRR NIH HHS / RR / M01 RR001032; United States / NIDCD NIH HHS / DC / R01 DC005672; United States / NCRR NIH HHS / RR / MO1 RR01032; United States / NIDCD NIH HHS / DC / R01 DC005672-08; United States / NIDCD NIH HHS / DC / R01 DC05672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS210338; NLM/ PMC2909757
  •  go-up   go-down


9. Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP: Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost; 2006 Mar;95(3):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
  • GPG-290 (100 microg/kg, n=6; 500 microg/kg, n=6) prolonged time to thrombotic occlusion (TTO) to 105+/-34 and 156+/-23 (p<0.05) min, respectively compared to the saline treated control group (32+/-6 min, n=6).
  • There was an increase in bleeding after the 500 microg/kg dose, but only at the 1 hr time point.
  • Clopidogrel was studied in two dosing regimens representing either a clinical pretreatment regimen (PTR) of 4.3 mg/kg on day -2 followed by 1.1 mg/kg daily for 2 days prior to the procedure or pre-procedural loading dose regimen (LDR) of 4.3 mg/kg 3 hr pre-procedure.
  • The PTR and LDR clopidogrel treatments prolonged TTO to 98.2+/-30.0 min and 136.1+/-39.5 min (p<0.05), and sustained patency in 1/6 and 4/8 vessels, respectively.
  • However, template bleeding time in the LDR clopidogrel group was sustained higher than the control group.
  • The combination of PTR clopidogrel and GPG-290 (100 microg/kg) prolonged TTO equivalent to LDR clopidogrel alone (141.4 +/- 35.1 min) and sustained patency in 3/7 dogs, without increased bleeding while LDR clopidogrel combined with 100 microg/kg GPG-290 prevented occlusion in 5/8 dogs and further prolonged TTO (173.5+/-32.6 min) but was associated with increased bleeding compared to control.
  • [MeSH-minor] Animals. Bleeding Time. Disease Models, Animal. Dogs. Dose-Response Relationship, Drug. Drug Therapy, Combination. Peptides / pharmacology. Platelet Aggregation / drug effects. Platelet Aggregation Inhibitors / pharmacology. Platelet Aggregation Inhibitors / therapeutic use. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / therapeutic use. Ticlopidine / analogs & derivatives. Ticlopidine / pharmacology. Ticlopidine / therapeutic use. Time Factors. Vascular Patency / drug effects. von Willebrand Factor / antagonists & inhibitors

  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525575.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Peptides; 0 / Platelet Aggregation Inhibitors; 0 / Platelet Glycoprotein GPIb-IX Complex; 0 / Recombinant Fusion Proteins; 0 / eptifibatide; 0 / glycocalicin; 0 / von Willebrand Factor; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine
  •  go-up   go-down


10. Yoshida S, Hayakawa K, Yamamoto A, Okano S, Kanda T, Yamori Y, Yoshida N, Hirota H: Quantitative diffusion tensor tractography of the motor and sensory tract in children with cerebral palsy. Dev Med Child Neurol; 2010 Oct;52(10):935-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: the aim of this study was to compare the findings of quantitative diffusion tensor tractography of the motor and sensory tracts in children with cerebral palsy (CP) and typically developed comparison individuals, and also to evaluate the correlation with gross motor function.
  • The following three diffusion tensor imaging (DTI) parameters including tractography were evaluated for each tract (corticospinal tract [CST] and posterior thalamic radiation [PTR]): number of fibres, tract-based fractional anisotropy, and region of interest (ROI)-based fractional anisotropy.
  • INTERPRETATION: DTI parameters of the CST and PTR in children with CP were significantly lower than in comparison children.

  • Genetic Alliance. consumer health - Cerebral Palsy.
  • MedlinePlus Health Information. consumer health - Cerebral Palsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dev Med Child Neurol. 2010 Oct;52(10):887 [20491853.001]
  • (PMID = 20412261.001).
  • [ISSN] 1469-8749
  • [Journal-full-title] Developmental medicine and child neurology
  • [ISO-abbreviation] Dev Med Child Neurol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Ishmael FT, Fang X, Galdiero MR, Atasoy U, Rigby WF, Gorospe M, Cheadle C, Stellato C: Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. J Immunol; 2008 Jun 15;180(12):8342-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glucocorticoids (GCs) are the mainstay of anti-inflammatory therapy.
  • Modulation of posttranscriptional regulation (PTR) of gene expression by GCs is a relevant yet poorly characterized mechanism of their action.
  • The RNA-binding protein tristetraprolin (TTP) plays a central role in PTR by binding to AU-rich elements in the 3'-untranslated region of proinflammatory transcripts and accelerating their decay.
  • To investigate the importance of PTR and the role of TTP in GC function, we compared the effect of GC treatment on genome-wide gene expression using mouse embryonic fibroblasts (MEFs) obtained from wild-type and TTP(-/-) mice.
  • These results reveal a strong and previously unrecognized contribution of PTR to the anti-inflammatory action of GCs and point at TTP as a key factor mediating this process through a complex mechanism of action.

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):1891-9 [10706852.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):79-97 [17561338.001]
  • [Cites] Mol Pharmacol. 2007 Oct;72(4):799-809 [17622575.001]
  • [Cites] J Allergy Clin Immunol. 2007 Dec;120(6):1247-63; quiz 1264-5 [18073120.001]
  • [Cites] J Biol Chem. 2008 Apr 25;283(17):11689-99 [18256032.001]
  • [Cites] Physiol Genomics. 2005 Sep 21;23(1):28-45 [15985639.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):222-30 [16113438.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):239-46 [16113441.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):247-54 [16113442.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):255-63 [16113443.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Jan;34(1):73-82 [16166738.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D111-4 [16381826.001]
  • [Cites] Eur Respir J. 2006 Feb;27(2):413-26 [16452600.001]
  • [Cites] Genes Cells. 2006 Mar;11(3):305-17 [16483318.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):120-30 [16421520.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):8161-8 [16439363.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23456-63 [16787927.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):4141-8 [16951379.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9126-35 [16982682.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(24):9196-208 [17030620.001]
  • [Cites] Arthritis Res. 2000;2(3):172-4 [11094425.001]
  • [Cites] Gene. 2001 Mar 7;265(1-2):11-23 [11255003.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25236-42 [11309384.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):9606-13 [11782475.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):195-205 [11994740.001]
  • [Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):945-52 [12440952.001]
  • [Cites] Cytokine. 2002 Nov 7;20(3):91-106 [12453467.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47444-50 [12356755.001]
  • [Cites] Neurochem Res. 2002 Oct;27(10):957-80 [12462398.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48558-64 [12324455.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13928-35 [12578839.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):19947-55 [12639954.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3554-61 [12789264.001]
  • [Cites] Genome Res. 2003 Aug;13(8):1863-72 [12902380.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4369-78 [14530362.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2003;75:43-68 [14604009.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21489-99 [15010466.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):27870-7 [15117938.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3092-102 [15257295.001]
  • [Cites] Trends Genet. 2004 Oct;20(10):491-7 [15363903.001]
  • [Cites] Science. 1991 Jul 19;253(5017):312-4 [1857966.001]
  • [Cites] Immunology. 1992 Jan;75(1):189-95 [1537596.001]
  • [Cites] Biochem Pharmacol. 1992 Oct 20;44(8):1569-76 [1417981.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):985-91 [8094998.001]
  • [Cites] Annu Rev Biochem. 1993;62:289-321 [8352591.001]
  • [Cites] Trends Biochem Sci. 1995 Nov;20(11):465-70 [8578590.001]
  • [Cites] Immunity. 1996 May;4(5):445-54 [8630730.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Science. 1998 Aug 14;281(5379):1001-5 [9703499.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15293-8 [9860962.001]
  • [Cites] Arthritis Res Ther. 2004;6(6):248-64 [15535838.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Jan;230(1):75-81 [15618129.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):953-61 [15634918.001]
  • [Cites] J Interferon Cytokine Res. 2005 Jan;25(1):1-10 [15684617.001]
  • [Cites] Biochem Pharmacol. 2005 Mar 1;69(5):733-40 [15710351.001]
  • [Cites] Mol Pharmacol. 2005 Jun;67(6):2148-61 [15778452.001]
  • [Cites] J Allergy Clin Immunol. 2007 Jan;119(1):115-22 [17208592.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26 [17245413.001]
  • [Cites] Genes Dev. 2007 Mar 15;21(6):719-35 [17369404.001]
  • [Cites] Mediators Inflamm. 2006;2006(6):40691 [17392586.001]
  • [Cites] Semin Immunol. 2000 Feb;12(1):85-98 [10723801.001]
  • (PMID = 18523301.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000511-10; United States / NIAID NIH HHS / AI / R01 AI060990-04; United States / NIAID NIH HHS / AI / R01 AI 060990-01A1; United States / NIAID NIH HHS / AI / AI060990-04; United States / NIAID NIH HHS / AI / R01 AI060990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / RNA-Binding Proteins; 0 / Tristetraprolin; 51333-22-3 / Budesonide
  • [Other-IDs] NLM/ NIHMS46516; NLM/ PMC2505276
  •  go-up   go-down


12. Casner PR, Sandoval E: Increased sensitivity to warfarin in elderly Hispanics. J Clin Pharmacol; 2002 Feb;42(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been suggested that aging enhances the pharmacologic effect of warfarin, but there is little information about the effects of warfarin in aging minority populations.
  • Charts in their anticoagulation clinic were retrospectively examined for the following information: age, sex, weight, duration of anticoagulant therapy, number of medical problems, number of medications, number of minor or major bleeding episodes, prothrombin time, warfarin dose, and international normalized ratio (INR).
  • The dose-adjusted prothrombin time ratio (PTR) and dose-adjusted INR were calculated by dividing the PTR and INR by the mean warfarin dose.
  • Elderly patients had more medical problems (3.1 vs. 2.4) and took more medications (3.4 vs. 2.4) than younger patients.
  • The dose-adjusted PTR and dose-adjusted INR increased with aging (0.59 vs. 0.38 and 0.85 vs. 0.59, p < .05 ANOVA).
  • [MeSH-minor] Data Interpretation, Statistical. Dose-Response Relationship, Drug. Female. Hispanic Americans. Humans. International Normalized Ratio. Male. Middle Aged. Partial Thromboplastin Time. Reference Values. Regression Analysis. Retrospective Studies. Texas

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11831536.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin
  •  go-up   go-down


13. Díaz R, Aparicio J, Gironés R, Molina J, Palomar L, Segura A, Montalar J: Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer; 2005 Sep;5(3):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
  • BACKGROUND: The objective of this study was to analyze prognostic factors for survival and to assess the applicability of Kohne's classification in patients treated with irinotecan- or oxaliplatin-based first-line chemotherapy.
  • Primary tumor resection (PTR) was performed in 80.6% of patients who initially had stage IV disease.
  • Chemotherapy consisted of fluoropyrimidines or raltitrexed plus irinotecan (50.5%), oxaliplatin (38.5%), or both (11%).
  • Significantly unfavorable prognostic factors were PTR not being performed, disease involvement of >1 organ, liver metastases, undifferentiated histology, EGOG PS>1, increased serum carcinoembryonic antigen and cancer antigen 19.9 levels, hypoalbuminemia, leucocytosis, and elevated alkaline phosphatase and lactate dehydrogenase (LDH) levels.
  • Only ECOG PS, PTR, increased LDH level, no hypoalbuminemia, and number of organs involved retained prognostic value in the multivariate analysis.
  • For patients with stage IV disease at presentation, PTR was associated with a significantly longer survival, mainly in patients with an ECOG PS of 0/1.
  • CONCLUSION: Eastern Cooperative Oncology Group PS, PTR, serum albumin, increased LDH levels, and organ involvement were the main prognostic indicators in our series.
  • Kohne's prognostic groups, developed in the era of 5-fluorouracil treatment, also seem to be applicable to patients treated with combination chemotherapy.
  • However, the benefit of PTR and multiple-agent chemotherapy is questionable in patients with an ECOG PS of >1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Predictive Value of Tests. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197623.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Kim ES, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK: Metaplastic ossification in a cutaneous pyogenic granuloma: a case report. J Dermatol; 2004 Apr;31(4):326-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous ossification may occur in association with a variety of cutaneous neoplasms and inflammatory conditions, such as pilomatricomas, basal cell carcinomas, nevi, chondroid syringomas, venous stasis, and scars.
  • However, it has rarely been reported in pyogenic granuloma, a relatively common benign vascular tumor of the skin and mucous membranes.
  • We herein presented a rare case of cutaneous pyogenic granuloma with ectopic ossification on the big toe of a 37-year-old man, with high recurrence despite repeated CO2 laser ablations.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Caustics / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Humans. Laser Therapy. Male. Ossification, Heterotopic / diagnosis. Ossification, Heterotopic / drug therapy. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery. Toes. Trichloroacetic Acid / administration & dosage

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TRICHLOROACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187328.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


15. Klein RL, Hirko AC, Meyers CA, Grimes JR, Muzyczka N, Meyer EM: NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res; 2000 Sep 1;875(1-2):144-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rats received intraseptal injections of either the control vector, pTR-UF4, or the pTR-NGFmyc at 3 months of age, prior to testing their performance in the Morris water task.
  • An age-related decrease in the acquisition of the hidden platform location was found at 12 months of age in the pTR-UF4 control group, but not in the pTR-NGFmyc group.
  • Further, when compared to 3 month old untreated animals, the control group, but not the pTR-NGFmyc group, was impaired at 12 months of age.
  • This approach may therefore represent a viable therapy for age-related dementia involving dysfunction in cholinergic activity and memory, such as Alzheimer's disease.
  • [MeSH-major] Aging / psychology. Memory Disorders / prevention & control. Nerve Growth Factor / pharmacology. Neurons / drug effects. Prosencephalon / drug effects. Space Perception / physiology
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Behavior, Animal / physiology. Cell Size. Choline O-Acetyltransferase / metabolism. Gene Expression. Gene Transfer Techniques. Male. Memory / physiology. Rats. Rats, Sprague-Dawley. Transgenes / physiology

  • MedlinePlus Health Information. consumer health - Memory.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10967308.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P01 AG 10485; United States / NINDS NIH HHS / NS / P01 NS 36302
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9061-61-4 / Nerve Growth Factor; EC 2.3.1.6 / Choline O-Acetyltransferase
  •  go-up   go-down


16. Miki H, Ozaki S, Tanaka O, Lee E, Takimoto T, Watanabe H, Fujii S, Nakamura S, Kagawa K, Takeuchi K, Yata K, Abe M, Kagami S, Matsumoto T: Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma. Int J Hematol; 2009 Mar;89(2):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.
  • We report a patient with refractory multiple myeloma (MM) who developed platelet transfusion refractoriness (PTR).
  • She underwent high-dose chemotherapy followed by autologous stem cell transplantation, and achieved a very good partial response.
  • Therefore, she was considered to have developed PTR due to anti-HLA class I antibody caused by the previous blood transfusions.
  • In addition, platelet transfusion from random donors showed clinical effects after BD therapy.
  • This case suggests that bortezomib might be effective in different types of immune disease by inhibiting allo-reactive antibody.
  • [MeSH-major] Boronic Acids / therapeutic use. Multiple Myeloma / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Antibodies. Bortezomib. Dexamethasone / therapeutic use. Female. HLA Antigens / immunology. Hematopoietic Stem Cell Transplantation. Humans. Middle Aged. Platelet Transfusion. Salvage Therapy. Transplantation, Homologous

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2005 Jun;129(6):776-83 [15953004.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1783-92 [17308121.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] Int J Hematol. 2007 Aug;86(2):180-5 [17875535.001]
  • [Cites] Haematologica. 2005 Feb;90(2):247-53 [15710579.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] Blood. 2006 Jul 15;108(2):551-8 [16537813.001]
  • [Cites] Leukemia. 2007 Jan;21(1):30-6 [17096016.001]
  • [Cites] Nat Med. 2008 Jul;14(7):748-55 [18542049.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • (PMID = 19225725.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Boronic Acids; 0 / HLA Antigens; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


17. Mirkovic T, Paver-Erzen V, Klokocovnik T, Gursahaney A, Hernandez P, Gottfried SB: Tracheal pressure regulated volume assist ventilation in acute respiratory failure. Can J Anaesth; 2007 Jun;54(6):420-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was hypothesized that regulating tracheal (Ptr) rather than airway opening pressure (Pao), to overcome endotracheal tube related resistive effort, during VAV would provide an effective alternative method of ventilation.
  • We therefore compared the effects of Pao and Ptr regulated VAV on breathing pattern and inspiratory effort.
  • METHODS: In seven intubated patients, flow, volume, Pao, Ptr, esophageal and transdiaphragmatic pressure were measured during VAV (0-80% respiratory system elastance) using Pao vs Ptr to regulate ventilator applied pressure.
  • Breathing pattern and the pressure-time integral of the inspiratory muscles (integralP(mus) .
  • dt) and diaphragm (integralP(di) .
  • dt) were determined.
  • dt = 39.6 +/- 7.5 vs 28.5 +/- 7.2 cm H(2)O.sec.L(-1), integralP(di) .
  • dt, = 35.4 +/- 7.8 vs 24.2 +/- 5.9 cm H(2)O.sec.L(-1), VAV 0 vs 80%; P < 0.05) due to a decrease in elastic related effort.
  • dt, and integralP(di) .
  • dt (which averaged 23.6 +/- 2.7, 33.7 +/- 4.4, and 38.5 +/- 5.1%, respectively; P < 0.05) for Ptr compared to Pao regulated VAV due to a decrease in resistive effort.
  • [MeSH-major] Respiration, Artificial. Respiratory Insufficiency / therapy. Trachea / physiology
  • [MeSH-minor] Acute Disease. Aged. Data Interpretation, Statistical. Diaphragm / physiopathology. Female. Humans. Intubation, Intratracheal. Male. Middle Aged. Oxygen / blood. Positive-Pressure Respiration. Pressure. Respiratory Mechanics / physiology. Respiratory Muscles / physiopathology. Tidal Volume / physiology. Transducers

  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Anaesth. 2007 Jun;54(6):407-13 [17541068.001]
  • (PMID = 17541070.001).
  • [ISSN] 0832-610X
  • [Journal-full-title] Canadian journal of anaesthesia = Journal canadien d'anesthésie
  • [ISO-abbreviation] Can J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


18. Naeser MA, Martin PI, Treglia E, Ho M, Kaplan E, Bashir S, Hamilton R, Coslett HB, Pascual-Leone A: Research with rTMS in the treatment of aphasia. Restor Neurol Neurosci; 2010;28(4):511-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Research with rTMS in the treatment of aphasia.
  • Part 2 also reviews our current rTMS treatment protocol used with nonfluent aphasia patients, and our functional imaging results from overt naming fMRI scans, obtained pre- and post- a series of rTMS treatments.
  • Part 3 presents results from a pilot study where rTMS treatments were followed immediately by constraint-induced language therapy (CILT).
  • Part 4 reviews our diffusion tensor imaging (DTI) study that examined white matter connections between the horizontal, midportion of the arcuate fasciculus (hAF) to different parts within Broca's area (pars triangularis, PTr; pars opercularis, POp), and the ventral premotor cortex (vPMC) in the RH and in the LH.

  • MedlinePlus Health Information. consumer health - Aphasia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 1999 Jan;41(1):13-20 [10025606.001]
  • [Cites] Stroke. 1999 Apr;30(4):749-54 [10187873.001]
  • [Cites] Arch Gen Psychiatry. 1999 Apr;56(4):315-20 [10197825.001]
  • [Cites] Stroke. 2006 Aug;37(8):2115-22 [16809569.001]
  • [Cites] J Neurosci. 2006 Aug 2;26(31):8069-73 [16885220.001]
  • [Cites] Cereb Cortex. 2006 Oct;16(10):1418-30 [16306320.001]
  • [Cites] Neurophysiol Clin. 2006 May-Jun;36(3):105-15 [17046605.001]
  • [Cites] J Int Neuropsychol Soc. 2006 Nov;12(6):828-42 [17064446.001]
  • [Cites] J Int Neuropsychol Soc. 2006 Nov;12(6):843-52 [17064447.001]
  • [Cites] Curr Opin Neurol. 2006 Dec;19(6):543-50 [17102691.001]
  • [Cites] Brain. 1996 Oct;119 ( Pt 5):1775-90 [8931597.001]
  • [Cites] Neuropsychol Rev. 2007 Jun;17(2):157-77 [17525865.001]
  • [Cites] Arch Neurol. 1971 Oct;25(4):302-6 [5110123.001]
  • [Cites] Brain. 1977 Mar;100 Pt 1:1-18 [861709.001]
  • [Cites] J Exp Psychol Hum Learn. 1980 Mar;6(2):174-215 [7373248.001]
  • [Cites] Int Rehabil Med. 1984;6(3):122-7 [6209235.001]
  • [Cites] Lancet. 1985 May 11;1(8437):1106-7 [2860322.001]
  • [Cites] Cortex. 1989 Dec;25(4):555-66 [2612175.001]
  • [Cites] Neuroimage. 1999 Dec;10(6):642-57 [10600410.001]
  • [Cites] Psychiatry Res. 1999 Nov 29;88(3):163-71 [10622338.001]
  • [Cites] Curr Opin Neurobiol. 2000 Apr;10(2):232-7 [10753803.001]
  • [Cites] Clin Neurophysiol. 2000 May;111(5):800-5 [10802449.001]
  • [Cites] Brain Lang. 2000 Jul;73(3):456-65 [10860566.001]
  • [Cites] Psychol Methods. 2000 Mar;5(1):87-101 [10937324.001]
  • [Cites] Stroke. 2000 Sep;31(9):2112-6 [10978039.001]
  • [Cites] J Commun Disord. 2000 Jul-Aug;33(4):357-66 [11001162.001]
  • [Cites] Neurology. 2000 Dec 26;55(12):1883-94 [11134389.001]
  • [Cites] J Cogn Neurosci. 2001 May 15;13(4):419-29 [11388916.001]
  • [Cites] Stroke. 2001 Jul;32(7):1621-6 [11441210.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):803-12 [12194878.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):720-3 [12221163.001]
  • [Cites] Neuron. 2002 Sep 26;36(1):159-70 [12367514.001]
  • [Cites] Neuroimage. 2002 Sep;17(1):174-83 [12482075.001]
  • [Cites] Neurosci Lett. 2003 Jan 16;336(2):131-3 [12499057.001]
  • [Cites] J Cogn Neurosci. 2003 Jan 1;15(1):71-84 [12590844.001]
  • [Cites] J Cogn Neurosci. 2003 Apr 1;15(3):444-61 [12729495.001]
  • [Cites] Clin Neurophysiol. 2003 May;114(5):777-98 [12738425.001]
  • [Cites] Brain Lang. 2003 Jun;85(3):357-68 [12744947.001]
  • [Cites] Ann Neurol. 2003 Sep;54(3):310-20 [12953263.001]
  • [Cites] Cerebrovasc Dis. 2004;17(1):35-43 [14530636.001]
  • [Cites] Neuroimage. 2003 Dec;20(4):1903-14 [14683696.001]
  • [Cites] Stroke. 2004 Feb;35(2):554-9 [14739418.001]
  • [Cites] Depress Anxiety. 2004;19(1):59-62 [14978787.001]
  • [Cites] Neuroimage. 1999 Jul;10(1):15-35 [10385578.001]
  • [Cites] J Comp Neurol. 1999 Sep 20;412(2):319-41 [10441759.001]
  • [Cites] Brain. 1999 Sep;122 ( Pt 9):1781-90 [10468516.001]
  • [Cites] Neuroimage. 2004 Nov;23(3):1046-58 [15528105.001]
  • [Cites] Trends Cogn Sci. 2004 Jun;8(6):273-9 [15165553.001]
  • [Cites] Am Psychol. 2004 Nov;59(8):692-704 [15554826.001]
  • [Cites] Neuroimage. 2005 Feb 1;24(3):656-66 [15652301.001]
  • [Cites] Physiology (Bethesda). 2005 Feb;20:60-9 [15653841.001]
  • [Cites] Brain Lang. 2005 Apr;93(1):95-105 [15766771.001]
  • [Cites] J Cogn Neurosci. 2005 Mar;17(3):392-406 [15814000.001]
  • [Cites] Cereb Cortex. 2005 Jun;15(6):854-69 [15590909.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1235-8 [15988526.001]
  • [Cites] Stroke. 2005 Jul;36(7):1462-6 [15947279.001]
  • [Cites] Curr Opin Neurol. 2005 Aug;18(4):429-34 [16003120.001]
  • [Cites] Neurocase. 2005 Jun;11(3):182-93 [16006338.001]
  • [Cites] Stroke. 2005 Aug;36(8):1759-63 [16020770.001]
  • [Cites] J Neurosci. 2005 Aug 31;25(35):8010-6 [16135758.001]
  • [Cites] J Neurosci. 2005 Sep 28;25(39):8854-66 [16192375.001]
  • [Cites] Neuroimage. 2005 Oct 15;28(1):194-204 [16009568.001]
  • [Cites] Brain Lang. 2006 Jul;98(1):57-65 [16519926.001]
  • [Cites] Brain Lang. 2006 Jul;98(1):118-23 [16564566.001]
  • [Cites] Brain. 2006 Jun;129(Pt 6):1371-84 [16638796.001]
  • [Cites] J Exp Anal Behav. 1994 Mar;61(2):281-93 [8169577.001]
  • [Cites] Brain. 1994 Aug;117 ( Pt 4):847-58 [7922470.001]
  • [Cites] Ann Neurol. 1995 Jun;37(6):723-32 [7778845.001]
  • [Cites] Brain. 1996 Jun;119 ( Pt 3):919-31 [8673502.001]
  • [Cites] Neurology. 1996 Dec;47(6):1504-11 [8960735.001]
  • [Cites] Neurology. 1997 May;48(5):1398-403 [9153480.001]
  • [Cites] J Neurosci Methods. 1997 Jun 27;74(2):113-22 [9219881.001]
  • [Cites] Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16 [9474057.001]
  • [Cites] Brain Lang. 1998 Apr;62(2):298-308 [9576825.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:527-65 [17444810.001]
  • [Cites] Curr Biol. 2007 Oct 9;17(19):1692-6 [17900904.001]
  • [Cites] Neurology. 2008 Jan 22;70(4):290-8 [18209203.001]
  • [Cites] J Cogn Neurosci. 2008 Apr;20(4):707-20 [18052789.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):451-3 [18096677.001]
  • [Cites] Neuroimage. 2008 Apr 15;40(3):1362-8 [18296070.001]
  • [Cites] Brain. 2008 May;131(Pt 5):1391-401 [18349055.001]
  • [Cites] J Physiol Paris. 2008 Jan-May;102(1-3):31-4 [18440208.001]
  • [Cites] Cortex. 2008 Sep;44(8):953-61 [18614162.001]
  • [Cites] Brain Lang. 2008 Oct;107(1):16-43 [17977592.001]
  • [Cites] J Neurosci. 2008 Nov 5;28(45):11435-44 [18987180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):18035-40 [19004769.001]
  • [Cites] Brain. 2008 Dec;131(Pt 12):3147-55 [18948300.001]
  • [Cites] J Neuroeng Rehabil. 2009;6:8 [19292910.001]
  • [Cites] Ann Neurol. 2009 May;65(5):577-85 [19475666.001]
  • [Cites] Brain Lang. 2009 Oct;111(1):20-35 [19695692.001]
  • [Cites] Clin Neurophysiol. 2009 Dec;120(12):2008-39 [19833552.001]
  • [Cites] Arch Phys Med Rehabil. 2009 Dec;90(12):2026-33 [19969164.001]
  • [Cites] Brain Lang. 2010 Jan;112(1):54-76 [18996582.001]
  • [Cites] Brain Lang. 2010 Apr;113(1):45-50 [20159655.001]
  • [Cites] Cogn Behav Neurol. 2010 Mar;23(1):29-38 [20299861.001]
  • [Cites] Cognition. 2004 May-Jun;92(1-2):179-229 [15037130.001]
  • [Cites] J Cogn Neurosci. 2004 Mar;16(2):289-300 [15068598.001]
  • [Cites] Neuroimage. 2004 May;22(1):29-41 [15109995.001]
  • [Cites] Neuroimage. 2004 May;22(1):42-56 [15109996.001]
  • [Cites] Annu Rev Neurosci. 2004;27:169-92 [15217330.001]
  • [Cites] Nat Neurosci. 2004 Jul;7(7):701-2 [15184903.001]
  • [Cites] Stroke. 2004 Sep;35(9):2171-6 [15297629.001]
  • [Cites] Brain Lang. 1998 Sep;64(2):215-30 [9710490.001]
  • [Cites] J Clin Neurophysiol. 1998 Jul;15(4):333-43 [9736467.001]
  • (PMID = 20714075.001).
  • [ISSN] 1878-3627
  • [Journal-full-title] Restorative neurology and neuroscience
  • [ISO-abbreviation] Restor. Neurol. Neurosci.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / RRO18875; United States / NIDCD NIH HHS / DC / P30 DC05207; United States / NIDCD NIH HHS / DC / P30 DC005207; United States / NCRR NIH HHS / RR / M01 RR001032; United States / NIDCD NIH HHS / DC / R01 DC005672; United States / NCRR NIH HHS / RR / MO1 RR01032; United States / NCRR NIH HHS / RR / K24 RR018875; United States / NCRR NIH HHS / RR / UL1 RR025758; United States / NIDCD NIH HHS / DC / R01 DC05672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS462034; NLM/ PMC3682778
  •  go-up   go-down






Advertisement